Unknown PHASE1 INTERVENTIONAL 1-arm NCT02937844

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme

Sponsor: Beijing Sanbo Brain Hospital

Conditions Glioblastoma Multiforme

Interventions Anti-PD-L1 CSR T cells Cyclophosphamide Fludarabine

Updated 6 times since 2017 Last updated: Oct 17, 2016 Started: Jul 31, 2016 Primary completion: Jul 31, 2018 Completion: Jul 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Glioblastoma Multiforme, this trial is ongoing. The trial is conducted by Beijing Sanbo Brain Hospital and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Aug 2019 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Aug 2019 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Sanbo Brain Hospital
Marino Biotechnology Co., Ltd.

Data source: Beijing Sanbo Brain Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China